Four Years of Data: Durability and Distinction with TYK2 Inhibition

In this video, Michael Cameron, MD, shares four years of data on TYK2 inhibition in psoriasis care, highlighting the durability and safety that continue to reinforce confidence in this once-daily oral therapy. He explains how TYK2’s selective allosteric mechanism differentiates it from traditional JAK inhibitors—helping to account for its clean long-term safety profile—and discusses where oral therapy fits into practice today. With insights on sustained PASI responses, special-site efficacy, and real-world convenience, Dr. Cameron outlines why TYK2 inhibition remains a distinct and durable option for systemic-eligible patients.